---
layout: post
title: "Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:37 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-03426
original_published: 2020-02-20 00:00:00 +0000
significance: 8.00
---

# Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** February 20, 2020 00:00 UTC
**Document Number:** 2020-03426

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance entitled "Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics." This guidance expands upon, consolidates, and supplements the recommendations on nonclinical immune system assessments provided across multiple guidance documents, most notably the International Conference on Harmonization (ICH) guidance for industry "S8 Immunotoxicity Studies for Human Pharmaceuticals." The topics covered include various aspects of immune suppression, modulation, and stimulation. This guidance replaces the withdrawn guidance entitled "Immunotoxicology Evaluation of Investigational New Drugs."

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/02/20/2020-03426/nonclinical-safety-evaluation-of-the-immunotoxic-potential-of-drugs-and-biologics-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2020-03426

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
